A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

This phase 1b, open-label, dose-escalation study assessed the safety, efficacy, and pharmacokinetics of anti-CD38 monoclonal antibody isatuximab given in 2 schedules (3, 5, or 10 mg/kg every other week [Q2W] or 10 or 20 mg/kg weekly [QW] for 4 weeks and then Q2W thereafter [QW/Q2W]), in combination...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Martin, Thomas, Baz, Rachid, Benson, Don M., Lendvai, Nikoletta, Wolf, Jeffrey, Munster, Pamela, Lesokhin, Alexander M., Wack, Claudine, Charpentier, Eric, Campana, Frank, Vij, Ravi
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482100/
https://ncbi.nlm.nih.gov/pubmed/28483761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-09-740787
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados